Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | TP53 | P04637 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | HTR3A | P46098 | 1/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.34 |
| ▸ | P2RX3 | P56373 | 5/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3052755 | 1.00 | CCR1 (0.38) | CCR1LMNATP53MAPTRXFP1 | |
| SCHEMBL3702612 | 0.85 | HRH4 (0.39) | CCR1MAPTHTR3AHRH4 | |
| SCHEMBL3046737 | 0.83 | HTR3A (0.36) | MAPTSMN1; SMN2HTR3AHRH4 | |
| SCHEMBL3046733 | 0.83 | HTR3A (0.36) | MAPTSMN1; SMN2HTR3AHRH4 | |
| SCHEMBL2672027 | 0.81 | HTR3A (0.36) | MAPTSMN1; SMN2HTR3AHRH4 | |
| SCHEMBL3042561 | 0.80 | KDM4E (0.47) | LMNAMAPTSMN1; SMN2HTR3AHRH4 | |
| SCHEMBL3059598 | 0.80 | KDM4E (0.47) | LMNAMAPTSMN1; SMN2HTR3AHRH4 | |
| SCHEMBL3880704 | 0.80 | HTR3A (0.35) | SMN1; SMN2HTR3AHRH4P2RX3 | |
| Trifluoroacetic Acid SCHEMBL2672176 | 0.80 | GPR6 (0.36) | CCR1SMN1; SMN2OPRK1HTR3AHRH4 | |
| SCHEMBL4072273 | 0.78 | CETP (0.37) | MAPTSMN1; SMN2HTR3AHRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222585-A1 | PREPARATION OF DIHYDROTHIENO [3, 2-D] PYRIMIDINES AND INTERMEDIATES USED THEREIN | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-02 | — | — | US | claimed |
| US-8653282-B2 | Preparation of dihydrothieno [3,2-D] pyrimidines and intermediates used therein | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-18 | — | — | US | disclosed |
| US-20100222585-A1 | PREPARATION OF DIHYDROTHIENO [3, 2-D] PYRIMIDINES AND INTERMEDIATES USED THEREIN | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222585-A1 | PREPARATION OF DIHYDROTHIENO [3, 2-D] PYRIMIDINES AND INTERMEDIATES USED THEREIN | DPYD, TYMS, DHFR | CCR1 993/4885LMNA 4078/4885TP53 633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.